Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biohaven Ltd. Common Shares
(NY:
BHVN
)
13.75
+0.38 (+2.84%)
Official Closing Price
Updated: 4:10 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biohaven Ltd. Common Shares
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Rise Above Previous 52-Week High
September 27, 2022
Via
Investor Brand Network
Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Exceed 52-Week High
September 26, 2022
Via
Investor Brand Network
Stocks That Hit 52-Week Highs On Friday
↗
September 23, 2022
On Friday, 5 companies hit new 52-week highs.
Via
Benzinga
Watch for Continued Gains in Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
September 23, 2022
Via
Investor Brand Network
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
↗
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Recap: Biohaven Pharma Hldgs Q2 Earnings
↗
August 05, 2022
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study
↗
May 23, 2022
Via
Benzinga
Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?
September 03, 2022
Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQ: VTRS), which produces products that treat diabetes,...
Via
MarketBeat
Biohaven Pharmaceutical's Return On Capital Employed Overview
↗
August 26, 2022
Benzinga Pro data, Biohaven Pharmaceutical (NYSE:BHVN) reported Q2 sales of $215.08 million. Earnings fell to a loss of $441.88 million, resulting in a 278.01% decrease from last quarter.
Via
Benzinga
$5.6 Million Bet On This Healthcare Stock? 3 Stocks Insiders Are Buying
↗
August 23, 2022
Although US stocks closed sharply lower on Monday, there were a few notable insider trades.
Via
Benzinga
Freedom Biosciences Gets $10.5M In Seed Financing For Psychedelics Research, This Is What We Know
↗
August 23, 2022
Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022
↗
August 19, 2022
Upgrades
Via
Benzinga
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
↗
August 08, 2022
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
↗
August 08, 2022
Via
Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
↗
August 05, 2022
Shares of Pfizer's rumored takeover target have rocketed for two days running.
Via
Investor's Business Daily
The 3 Best Market Sectors for the Second Half of 2022
↗
July 27, 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into.
Via
InvestorPlace
Which Coronavirus Stock Could Fetch Higher Returns?
↗
July 11, 2022
This article will compare Pfizer, Moderna, and Novavax to see which of these coronavirus stocks will yield the highest returns.
Via
InvestorPlace
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
July 06, 2022
From
Global Coalition for Adaptive Research
Via
Business Wire
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
↗
July 05, 2022
The FDA's advisors recently backed Pfizer's Covid shot for young children.
Via
Investor's Business Daily
Hopeful Golden Cross Forms On Biohaven Pharma Hldgs's Chart
↗
June 23, 2022
If history is any guide, there may be good fortune ahead for shares of Biohaven Pharma Hldgs (NYSE:BHVN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish...
Via
Benzinga
Looking Into Biohaven Pharmaceutical's Return On Capital Employed
↗
June 10, 2022
According to data from Benzinga Pro, during Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $318.85 million. Despite a 41.43% increase in earnings, the company posted a loss of $116.90...
Via
Benzinga
3 Biotech Stocks to Buy Before They Boom
↗
June 01, 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.
Via
InvestorPlace
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
↗
May 24, 2022
The company is planning to soon ask for FDA approval of etrasimod in ulcerative colitis.
Via
Investor's Business Daily
BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN
May 17, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
↗
May 16, 2022
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from...
Via
Benzinga
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review
↗
May 13, 2022
Elon Musk put his Twitter deal "on hold" but says he's "still committed" to it.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
↗
May 11, 2022
Upgrades
Via
Benzinga
103 Biggest Movers From Yesterday
↗
May 11, 2022
Gainers
Via
Benzinga
Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?
↗
May 10, 2022
BHVN stock is enjoying a nearly 70% jump today after Biohaven Pharmaceutical announced it has been acquired by Pfizer.
Via
InvestorPlace
Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; Crude Oil Down 3%
↗
May 10, 2022
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.